A systematic review of approaches for engaging patients for research on rare diseases

Journal of General Internal Medicine

Volumn 29, Issue SUPPL. 3, 2014, Pages

  Forsythe, Laura P ^a   Szydlowski, Victoria ^a   Murad, Mohammad Hassan ^b   Ip, Stanley ^a   Wang, Zhen ^b   Elraiyah, Tarig A ^b   Fleurence, Rachael ^a   Hickam, David H ^a  

^a PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

engagement; rare diseases; systematic review

Indexed keywords

HUMAN; MEDICAL RESEARCH; METHODOLOGY; PATIENT PARTICIPATION; RARE DISEASE;

BIOMEDICAL RESEARCH; HUMANS; PATIENT PARTICIPATION; RARE DISEASES; RESEARCH DESIGN;

EID: 84905911810     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2895-9     Document Type: Review

References (61)

1. Andersen T. The political empowerment of rare disease patient advocates both at EU and national level. Orphanet Journal Of Rare Diseases. 2012;7(2):A33.
2. European Organization for Rare Diseases (EURORDIS). Patients' priorities and needs for rare disease research 2014-2020. Available at: http://www.eurordis.org/sites/default/files/publications/what-how%20-are- disease-research-0.pdf Accessed April 30, 2014.
3. Forsythe LP, Frank L, Walker KO, Hayes D, Levine S, Anise A, et al., editors. Patient and Clinician Views on Comparative Effectiveness Research and Engagement in Research: A Panel Discussion on PCORI Survey Results. Academy Health Annual Research Meeting; 2013 June 2013; Baltimore, MD.
4. Landy DC, Brinich MA, Colten ME, Horn EJ, Terry SF, Sharp RR. How disease advocacy organizations participate in clinical research: a survey of genetic organizations. Genet Med. 2012;14(2):223-228. doi:10.1038/gim.0b013e3182310ba0.
5. Concannon TW, Meissner P, Grunbaum JA, McElwee N, Guise JM, Santa J, et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J Gen Intern Med. 2012;27(8):985-991.
6. Carman KL, Dardess P, Maurer M, Sofaer S, Adams K, Bechtel C, et al. Patient and family engagement: a framework for understanding the elements and developing interventions and policies. Health Aff (Millwood). 2013;32(2):223-231. doi:10.1377/hlthaff.2012.1133.
7. Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, et al. Fibromyalgia syndrome. J Rheumatol. 2007;34(6):1415-1425. (Pubitemid 46898129)
8. Caron-Flinterman JF, Broerse JEW, Bunders JFG. The experiential knowledge of patients: a new resource for biomedical research? Soc Sci Med. 2005;60(11):2575-2584. (Pubitemid 40462381)
9. Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N, et al. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14(1):89. doi:10.1186/1472-6963-14-89.
10. Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, et al. Patient-important outcomes in registered diabetes trials. JAMA. 2008;299(21):2543-2549. (Pubitemid 351787210)
11. Nass P, Levine S, Yancy C. Methods for involving patients in topic generation for patient-centered comparative effectiveness research: An international perspective; 2012. Available at: http://www.pcori.org/assets/ Methods-for-Involving-Patients-in-Topic-Generation-for-Patient-Centered- Comparative-Effectiveness-Research-%E2%80%93-An-Inter-national-Perspective.pdf. ; Accessed April 30, 2014.
12. Staley K. Exploring Impact: Public involvement in NHS, public health and social care research; 2009.
13. Shippee ND, Domecq GJP, Prutsky LGJ, Wang Z, Elraiyah TA, Nabhan M, et al. Patient and service user engagement in research: a systematic review and synthesized framework. Health Expectations. 2013. doi:10.1111/hex.12090.
14. Hanley B BJ, Gorin S, Barnes M, Goodare H, Kelson M, Kent A, Oliver S, Thomas S, Wallcraft J. Involving the public in NHS, public health and social care research: briefing notes for researchers. 2nd ed. . 2004. Available at: http://www.twocanassociates.co.uk/perch/resources/files/Briefing%20Note%20Final- dat(2).pdf. Accessed April 30, 2014.
15. National Organization for Rare Disorders (NORD). Rare Disease Information. 2013. Available at: http://www.rarediseases.org/rare-disease- information. Accessed April 30, 2014.
16. National Institutes of Health(NIH). Genetic and Rare Disease Information Center. Available at: http://rarediseases.info.nih.gov/gard/browse-by-first- letter/A. Accessed April 30, 2014.
17. Patient-Centered Outcomes Research Institute (PCORI). The PCORI Methodlogy Report. 2013. Avialable at: http://www.pcori.org/assets/2013/11/ PCORI-Methodology-Report.pdf. Accessed April 30, 2014.
18. Carroll R, Antigua J, Taichman D, Palevsky H, Forfia P, Kawut S, et al. Motivations of patients with pulmonary arterial hypertension to participate in randomized clinical trials. Clinical trials (London, England) 2012;9(3):348-57. doi:10.1177/1740774512438981
19. Edwards V, Wyatt K, Logan S, Britten N. Consulting parents about the design of a randomized controlled trial of osteopathy for children with cerebral palsy. Health Expectations. 2011;14(4):429-438. doi:10.1111/j.1369-7625.2010. 00652.x.
20. Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in viti l igo trials. Br J Dermatol . 2012;167(4):804-814. doi:10.1111/j.13652133.2012.11056.x
21. Fern LA, Taylor RM, Whelan J, Pearce S, Grew T, Brooman K, et al. The art of age-appropriate aare: reflecting on a conceptual model of the cancer experience for teenagers and young adults. Cancer Nurs. 2013;36(5):E27-e38. doi:10.1097/NCC.0b013e318288d3ce
22. Mavris M, Le Cam Y. Involvement of patient organisations in research and development of orphan drugs for rare diseases in Europe. Mol Syndromol. 2012;3(5):237-243.
23. Nierse CJ, Abma TA, Horemans AM, van Engelen BG. Research priorities of patients with neuromuscular disease. Disabil Rehabil. 2013;35(5):405-12. doi:10.3109/09638288.2012.694964
24. Rothwell E, Anderson RA, Swoboda KJ, Stark L, Botkin JR. Public attitudes regarding a pilot study of newborn screening for spinal muscular atrophy. Am J Med Genet A. 2013;161A(4):679-686.
25. Serrano-Aguilar P, Trujillo-Martin MM, Ramos-Goni JM, Mahtani-Chugani V, Perestelo-Perez L, Posada-de la Paz M. Patient involvement in health research: a contribution to a systematic review on the effectiveness of treatments for degenerative ataxias. Soc Sci Med. 2009;69(6):920-5. doi:10.1016/j.socscimed. 2009.07.005
26. Wu R, Zhang J, Luke KH, Wu X, Burke T, Tang L, et al. Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China. Health Qual Life Outcomes. 2012;10:112. doi:10.1186/1477-7525-10-112
27. Bedgood R, Sadurski R, Schade RR. The use of the internet in data assimilation in rare diseases. Dig Dis Sci. 2007;52(2):307-312. (Pubitemid 46202797)
28. Boon W, Broekgaarden R. The role of patient advocacy organisations in neuromuscular disease R&D-The case of the Dutch neuromuscular disease association VSN. Neuromuscul Disord. 2010;20(2):148-51. doi:10.1016/j.nmd.2009. 10.012
29. Bruinsma FJ, Rayner JA, Venn AJ, Pyett P, Werther G. Looking back in time: conducting a cohort study of the long-term effects of treatment of adolescent tall girls with synthetic hormones. BMC Public Health. 2011;11(5):S7.
30. de Blieck EA, Augustine EF, Marshall FJ, Adams H, Cialone J, Dure L, et al. Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates. Contemp Clin Trials. 2013;35(2):48-54. doi:10.1016/j.cct.2013.04.004
31. DeWard SJ, Wilson A, Bausell H, Volz AS, Mooney K. Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience. J Genet Couns. 2014;23(1):20-8. doi:10.1007/s10897-013-9642-y
32. European Medicine Agency (EMA). The role of patients as members of the EMA Human Scientific Committees. Available at: http://www.ema.europa.eu/docs/en- GB/document-library/Other/2011/12/WC500119614.pdf. Accessed April 30, 2014.
33. European Medicines Agency (EMA). Fifth report on the interaction with patients' and consumers' organizations 2011. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Report/2012/10/WC500133475.pdf. Accessed April 30, 2014.
34. European organisation for rare diseases (EURORDIS). Activity Report 2012 & Workplan 2013. Available at: http://www.eurordis.org/sites/default/files/ activity-report-2012.pdf. Accessed April 30, 2014.
35. Langston AL, McCallum M, Campbell MK, Robertson C, Ralston SH. An integrated approach to consumer representation and involvement in a multicentre randomized controlled trial. Clinical Trials. 2005;2(1):80-87. (Pubitemid 40332931)
36. Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, et al. Li-Fraumeni syndrome: Report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012;205(10):479-487.
37. Marshall E. Genetics. Patient advocate named co-inventor on patent for the PXE disease gene. Science. 2004;305(5688):1226. doi:10.1126/science.305. 5688.1226a. (Pubitemid 39129204)
38. McCormack P, Woods S, Aartsma-Rus A, Hagger L, Herczegfalvi A, Heslop E, et al. Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "TRANSLATING" the translational. 2013(JAN):1-17.
39. Molster C, Youngs L, Hammond E, Dawkins H. Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases. 2012;7:50. doi:10.1186/1750-1172-7-50.
40. Ntshanga SP, Ngcobo PS, Mabaso ML. Establishment of a Community Advisory Board (CAB) for tuberculosis control and research in the Inanda, Ntuzuma and KwaMashu (INK) area of KwaZulu-Natal, South Africa. Health Policy. 2010;95(2-3):211-215. doi:10.1016/j.healthpol.2009.12.004.
41. Schwartz ME, Zimmerman GM, Smith F, Sprecher E. Pachyonychia congenita project: A partnership of patient and medical professional. 2013;5(1):42-7. doi:10.1097/JDN.0b013e31827d9ed5.
42. Seminara J, Tuchman M, Krivitzky L, Krischer K, Lee HS, Lemons C, et al. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab. 2010;100(1):S97-S105.
43. Workman TA. Engaging patients in information sharing and data collection: The role of patient-powered registries and research networks prepared for AHRQ. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/assets/File/Patient- Powered-Registries-white-paper-130911.pdf Accessed April 30, 2014.
44. European Patients 'Academy on Therapeutic Innovation (EUPATI). EUPATI (European Patients' Academy on Therapeutic Innovation). Available at: http://www.patientsacademy.eu/. Accessed April 30, 2014.
45. Orphanet. Researchers' wish-list for rare disease research in Europe. Available at: http://www.orpha.net/actor/EuropaNews/2005/050715.html. Accessed April 30, 2014.
46. Rare disease matters. Patient-initiated research foundations. Available at: http://www.rarediseasematters.org/role-of-patient/patient-initiated- research-foundations-a-source-of-funding-but-more-importantly-a-con-tinuous- source-of-inspiration/. Accessed April 30 2014.
47. The Cystic Fibrosis Foundation. Theraputic Developments Network. Available at: http://www.cff.org/research/TDN/. Accessed April 30, 2014.
48. The Lupus Research Institute. A patient's voice in lupus research. Available at: http://www.lupusresearchinstitute.org/news/discoveries/09- advocacy. Accessed April 30 2014.
49. The Parkinson Pipeline Project. The Parkinson Pipeline Project. Available at: http://www.pdpipeline.org/. Accessed April 30, 2014.
50. von Hippel-Lindau Alliance. von Hippel-Lindau Alliance, Available at: http://www.vhl.org/wordpress/ Accessed April 30, 2014.
51. Workman T, Maurer M, Carman K. Unresolved tensions in consumer engagement in CER: a US research perspective. Journal of Comparative Effectiveness Research. 2013;2:127.
52. Schaefer E, Astigarraga I, Haupt R, Minkov M, Price R, Donadieu J. Histio Net-A reference network for the creation of an international web portal for Langerhans cell histiocytosis and associated syndromes. Pediatric Blood and Cancer. 2011;56 (4):693.
53. Mullins CD, Abdulhalim AM, Lavallee DC. Continuous patient engagement in comparative effectiveness research. JAMA. 2012;307(15):1587-1588. doi:10.1001/jama.2012.442.
54. Colorado Clinical and Translational Sciences Institute (CCTSI). Colorado Clinical and Translational Sciences Institute (CCTSI). Available at: http://cctsi.ucdenver.edu/Pages/index.aspx. Accessed April 30, 2014.
55. Recommendations for Community Involvement in National Institute of Allergy and Infectious Diseases HIV/AIDS Clinical Trials Research 2009. Available at: http://www.hvtn.org/community/CAB-Recommendations-Certified.pdf. Accessed April 30, 2014
56. Faster Cures. Back to Basics: HIV/AIDS Advocacy as a Model for Catalyzing Change. Available at: http://www.fastercures.org/assets/Uploads/PDF/ Back2BasicsFinal.pdf. Accessed April 30, 2014.
57. Patient-Centered Outcomes Research Institute (PCORI). PCORI Mission and Vision. Available at: http://www.pcori.org/about-us/mission-andvision/. Accessed April 30, 2014.
58. Patient-Centered Outcomes Research Institute (PCORI). PCORI Funding Center. Available at: http://www.pcori.org/funding-opportunities/funding-center/ . Accessed April 30, 2014.
59. Agency for Healthcare Research and Quality (AHRQ). Effective Healthcare Program Helping You Make Better Choices. Available at: http:// effectivehealthcare.ahrq.gov/index.cfm/who-is-involved-in-the-effective-health- care-program1/ahrq-community-forum/ Accessed April 30, 2014.
60. Patient-Centered Outcomes Research Institute (PCORI). PCORnet: The National Patient-Centered Clinical Research Network. 2013. Available at: http://www.pcori.org/funding-opportunities/pcornet-national-patient-centered- clinical-research-network/ Accessed April 30, 2014.
61. Patient-Centered Outcomes Research Institute (PCORI). PCORI Proposed Charter for the Advisory Panel on Rare Diseases. Available at: http://www.pcori.org/assets/2013/11/PCORI-Board-Meeting-Proposed-Charter- Advisory-Panel-on-Rare-Disease-111813.pdf. Accessed April 30, 2014.